JP2023552368A - Ｙボックス結合タンパク質１阻害剤 - Google Patents

Ｙボックス結合タンパク質１阻害剤 Download PDF

Info

Publication number
JP2023552368A
JP2023552368A JP2023533819A JP2023533819A JP2023552368A JP 2023552368 A JP2023552368 A JP 2023552368A JP 2023533819 A JP2023533819 A JP 2023533819A JP 2023533819 A JP2023533819 A JP 2023533819A JP 2023552368 A JP2023552368 A JP 2023552368A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
cancer
group
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533819A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023552368A5 (enExample
Inventor
サンジャイ ブイ． マルホトラ
ダニール テイラー
アーピット ディーライ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oregon Health & Science University
Leland Stanford Junior University
Original Assignee
Oregon Health & Science University
Leland Stanford Junior University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oregon Health & Science University, Leland Stanford Junior University filed Critical Oregon Health & Science University
Publication of JP2023552368A publication Critical patent/JP2023552368A/ja
Publication of JP2023552368A5 publication Critical patent/JP2023552368A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023533819A 2020-12-04 2021-12-03 Ｙボックス結合タンパク質１阻害剤 Pending JP2023552368A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063121674P 2020-12-04 2020-12-04
US63/121,674 2020-12-04
US202163256609P 2021-10-17 2021-10-17
US63/256,609 2021-10-17
PCT/US2021/061906 WO2022120242A1 (en) 2020-12-04 2021-12-03 Y box binding protein 1 inhibitors

Publications (2)

Publication Number Publication Date
JP2023552368A true JP2023552368A (ja) 2023-12-15
JP2023552368A5 JP2023552368A5 (enExample) 2024-11-29

Family

ID=81853609

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533819A Pending JP2023552368A (ja) 2020-12-04 2021-12-03 Ｙボックス結合タンパク質１阻害剤

Country Status (6)

Country Link
US (1) US20240016784A1 (enExample)
EP (1) EP4255426A4 (enExample)
JP (1) JP2023552368A (enExample)
AU (1) AU2021391931A1 (enExample)
CA (1) CA3201032A1 (enExample)
WO (1) WO2022120242A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4554587A4 (en) * 2022-07-12 2026-07-01 Univ Oregon Health & Science ENANTIOMER OF AZOPODOPHYLLOTOXINE DERIVATIVE SU056
US20240180881A1 (en) * 2022-11-17 2024-06-06 National Institute Of Immunology Methods for decreasing resistance to chemotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017151947A1 (en) * 2016-03-02 2017-09-08 George Robert Pettit 4-azapodophylotoxins compounds
WO2019178091A1 (en) * 2018-03-13 2019-09-19 The Board Of Trustees Of The Leland Stanford Junior University Novel n-hydroxyethyl didehydroazapodophyllotoxins as gbp1 inhibitors and methods of overcoming treatment resistance in cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170342086A1 (en) * 2015-02-26 2017-11-30 Ajay Kumar Compounds and methods for the treatment of drug resistance in cancer cells against paclitaxel
WO2017207616A1 (en) * 2016-05-31 2017-12-07 Celltrend Gmbh Diagnosis of cancer by detecting auto-antibodies against y box binding protein (yb-1)
CN116761602A (zh) * 2020-12-04 2023-09-15 俄勒冈健康与科学大学 Y盒结合蛋白质1抑制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017151947A1 (en) * 2016-03-02 2017-09-08 George Robert Pettit 4-azapodophylotoxins compounds
WO2019178091A1 (en) * 2018-03-13 2019-09-19 The Board Of Trustees Of The Leland Stanford Junior University Novel n-hydroxyethyl didehydroazapodophyllotoxins as gbp1 inhibitors and methods of overcoming treatment resistance in cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CELL CHEMICAL BIOLOGY, vol. 28, JPN6025046584, 2021, pages 1206 - 1220, ISSN: 0005884362 *

Also Published As

Publication number Publication date
CA3201032A1 (en) 2022-06-09
AU2021391931A1 (en) 2023-06-29
WO2022120242A1 (en) 2022-06-09
EP4255426A1 (en) 2023-10-11
US20240016784A1 (en) 2024-01-18
EP4255426A4 (en) 2024-10-23

Similar Documents

Publication Publication Date Title
TWI623533B (zh) 作為檢測點激酶1 (chk1)抑制劑之3,5-二取代吡唑及其製備及應用
US9073916B2 (en) Prodrug forms of kinase inhibitors and their use in therapy
EP3791897A1 (en) Hsp90 inhibitor drug conjugates
CA3133688A1 (en) Compositions and methods for treating cancer
CN106715443A (zh) Fl118母核化学结构平台产生用于治疗人类疾病的fl118衍生物的用途
AU2014344789B2 (en) Pharmaceutical combinations for the treatment of cancer
Banerjee et al. X-ray crystallography-guided design, antitumor efficacy, and QSAR analysis of metabolically stable cyclopenta-pyrimidinyl dihydroquinoxalinone as a potent tubulin polymerization inhibitor
US9795595B2 (en) Methods for treating cancer
WO2020132259A1 (en) Compositions and methods of treating cancers by administering a phenothiazine-related drug that activates protein phosphatase 2a (pp2a)
US20150274742A1 (en) Treating Brain Cancer using Agelastatin A (AA) and Analogues Thereof
CN110573166A (zh) 用于癌症治疗的吉西他滨衍生物
KR20250033298A (ko) 아조포도필로톡신 유도체 su056의 거울상이성질체
JP2016502509A (ja) がんを治療するのに有効なインゲノール誘導化合物
US20240016784A1 (en) Y box binding protein 1 inhibitors
CN104470509A (zh) 剂量范围在2至30mg/kg的地塞米诺或其衍生物在癌症治疗中的用途
EP4495121A1 (en) Camptothecin derivatives that bind to ddx5 protein and prodrugs thereof
AU2014280354A1 (en) Combinations for the treatment of cancer comprising a Mps-1 kinase inhibitor and a mitotic inhibitor
CN116761602A (zh) Y盒结合蛋白质1抑制剂
KR20200016874A (ko) 표적화 치료제를 포함하는 병용 요법
CN104837814A (zh) 新型化合物及其用途
WO2018017589A1 (en) Compounds for targeting cancer stem cells
US20230212202A1 (en) Treatment of mgmt deficient cancer with 2-fluoroethyl-substituted nitrosoureas and other compounds
KR20130130802A (ko) 보르트만닌 유사체의 결정질 형태의 조성물 및 이의 사용 방법
JP2024515727A (ja) チューブリン重合阻害剤としての代謝的に安定なピリミジニルジヒドロキノキサリノン
WO2025132831A1 (en) N-heteroaryl derivatives and uses thereof for treating cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241121

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241121

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251112

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260408

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260512

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260615